Macfarlan Smith, a subsidiary of Veranova, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Edinburgh, UK facility. The multi-purpose asset, able to handle highly active APIs and intermediates, is positioned to enable growth in the generic opioid analgesic and anti-addiction markets, while also supporting the growing demands of Veranova’s existing customer base and unlocking future growth. “This investment will ...